Method of preparing adenosine-resistant anti-tumor t lymphocytes for adoptive immunotherapy
AssigneeNortheastern University
InventorsMichail V. Sitkovsky, Akio Ohta
Life of this patent
Estimating the term…
Abstract
In the past, adoptive immunotherapy often failed because the transferred immune cells were inactive in vivo. This disclosure provides a method of producing immune cells that are highly active in vivo. The immune cells may be expanded in vitro in the presence of an adenosine receptor agonist or an antisense nucleic acid that downregulates expression of an adenosine receptor, for example. The immune cells may be tumor-infiltrating lymphocytes (TIL), cytotoxic T lymphocytes (CTL), natural killer (NK) cells, or lymphokine-activated killer (LAK) cells, for example. The methods described herein may be used to treat a number of diseases including cancer, infectious diseases, and immunodeficiencies.
Claims30
A composition comprising an in vitro cultured mammalian lymphocyte population, wherein said lymphocyte population was cultured in the presence of an adenosine receptor agonist.
(canceled)
7-8. (canceled)
10-12. (canceled)
15-17. (canceled)
A composition comprising a lymphocyte, an adenosine receptor agonist, and a nucleic acid encoding a recombinant T cell receptor specific to a desired antigen.
21-23. (canceled)
25-27. (canceled)
A method of making a lymphocyte preparation, comprising:
- (a) collecting a lymphocyte population from a subject;
- and (b) culturing said lymphocyte population in vitro in a culture medium in the presence of an agonist of an adenosine receptor.
(canceled)
(canceled)
37-38. (canceled)
A method of treating cancer, an infectious disease, and/or an immune-deficiency in a subject in need thereof, comprising administering to said subject a lymphocyte population, in a therapeutically effective amount, wherein said population was cultured in the presence of an adenosine receptor agonist.
40-53. (canceled)
Dependencies are inferred from the claim text.